Alopecia areata is an autoimmune condition that causes hair loss when the immune system mistakenly attacks healthy hair follicles. For children, this condition can be especially distressing—affecting their confidence and emotional well-being. At PedSkin Research in Miami, we’re dedicated to helping families understand alopecia areata, explore treatment options, and gain access to the latest clinical research available for children and adolescents.

Alopecia areata can appear as small bald patches on the scalp or, in more severe cases, lead to widespread hair loss. The condition is not contagious, and it does not reflect poor health or hygiene. Instead, it stems from an autoimmune reaction that targets the hair follicles.

In children, this can happen suddenly and without pain or itching. Some may experience regrowth cycles where hair falls out and then grows back over time. While there is no FDA-approved cure specifically for pediatric alopecia areata, advancements in research are creating new hope for long-term management and regrowth.

Pediatric dermatologists often tailor treatments to each child’s age, the extent of hair loss, and how they respond over time. Some of the most common approaches include:

• Topical Corticosteroids – Applied directly to affected areas to reduce inflammation and help restart hair growth.
• Topical Immunotherapy – Uses mild chemical agents to trigger an immune response that can encourage regrowth.
• Minoxidil – Often prescribed off-label to promote hair regrowth in children, particularly for mild to moderate cases.
• Light Therapy (Phototherapy) – Uses specific wavelengths of light to stimulate hair follicles and reduce inflammation.

While these treatments may offer improvement, many families seek more advanced, research-based therapies—especially for moderate to severe cases.

PedSkin Research currently offers clinical trials for children and adolescents with alopecia areata, providing access to innovative treatment options not yet available to the public.

Active Studies Include:

• Ritlecitinib (Litfulo) – A Pfizer oral JAK inhibitor for children aged 6 to 11 years old.
• Baricitinib (Olumiant) – An FDA-approved JAK inhibitor for individuals aged 12 years and older.

These trials focus on children and teens with moderate to severe alopecia areata, where more than half of the scalp is affected. The goal is to assess the effectiveness and safety of these next-generation medications in promoting hair regrowth and improving quality of life.

Participating in a clinical trial allows families to play an active role in advancing pediatric dermatology and may provide early access to cutting-edge therapies.

Hair loss can have a significant emotional impact on children. Parents can help by:

• Encouraging open conversations about feelings and self-image.
• Providing reassurance that alopecia areata is a medical condition and not their fault.
• Exploring creative options like hats, scarves, or hairstyles that boost confidence.
• Joining support communities for families navigating similar challenges.

At PedSkin Research, we understand that treating alopecia areata is not only about hair—it’s about helping children feel comfortable and confident in their own skin.

If your child is between the ages of 6 and 17 and has been diagnosed with moderate to severe alopecia areata, they may qualify for one of our ongoing clinical trials in Miami.

Our studies are designed to provide a safe and supportive environment for children while exploring the most advanced treatment options available today.